Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Bausch Health Separation Of The Eye Care Business


NYSE:BHC ban facial recognition surveillance

In a new report Xtract Research examines issues associated with the potential separation by Bausch Health Companies Inc (NYSE:BHC) of its eye care business.

Get Our Activist Investing Case Study!

Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!

Q1 2021 hedge fund letters, conferences and more

Issues With The Separation Of Bausch Health's Eye Care Business

Highlights from the report include:

Under both high yield bonds and leveraged loans, generally the only way to make the Restricted Payment required for the dividend in a spin-off is pursuant to: (1) the RP Buildup basket/Available Amount; (2) general RP basket; (3) if present, a Ratio RP exception limited only by compliance with a specified pro forma leverage ratio; and (4) the Neiman Two Step dividend (using investment capacity to unrestrict the business (step one) and then using the carveout for the distribution of the stock of an Unsub (step two). BHC’s debt documents include all these provisions.

In the absence of RP capacity to pay the dividend, the company would have to structure the separation in another way, take out the restrictive debt or obtain consent from its creditors. Unless required in connection with any consent, a spin-off would not mandate that any debt be repaid.

If the company were to remove the business via a sale, two main considerations are: (1) mandated use of proceeds (ie, which debt must or may be repaid); and (2) whether the sale rises to the level of substantially all assets (which would also implicate change of control).

The separated business, regardless of how it is removed, will no longer provide credit support to remainco’s debt, and its guarantees and, for the secured debt, its pledge, will be released. So, in the case of a spin off, the quantum of Bausch Pharma debt may not be reduced, but the assets supporting that debt certainly will be.

If the company goes down the spin-off/amendment route, lenders could require paydowns as part of the approval process. Bondholders would be left out assuming valuation talk is accurate.

The post Bausch Health Separation Of The Eye Care Business appeared first on ValueWalk.


Source valuewalk

Like: 0
Share

Comments